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Abstract
Aims: We asked whether the neuroprotective effect of cholinergic microglial stimulation during an ischemic
event acts via a mechanism involving the activation of nuclear factor erythroid-2-related factor 2 (Nrf2) and/or
the expression of its target cytoprotective gene, heme oxygenase-1 (HO-1). Specifically, the protective effect of the
pharmacologic alpha-7 nicotinic acetylcholine receptor (a7 nAChR) agonist PNU282987 was analyzed in orga-
notypic hippocampal cultures (OHCs) subjected to oxygen and glucose deprivation (OGD) in vitro as well as in
photothrombotic stroke in vivo. Results: OHCs exposed to OGD followed by reoxygenation elicited cell death,
measured by propidium iodide and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide staining. Ac-
tivation of a7 nAChR by PNU282987, after OGD, reduced cell death, reactive oxygen species production, and
tumor necrosis factor release. This was associated with induction of HO-1 expression, an effect reversed by a-
bungarotoxin and by tin–protoporphyrin IX. The protective effect of PNU282987 was lost in microglial-depleted
OHCs as well as in OHCs from Nrf2-deficient-versus-wild-type mice, an effect associated with suppression of HO-
1 expression in microglia. Administration of PNU282987 1h after induction of photothrombotic stroke in vivo
reduced the infarct size and improved motor skills in Hmox1lox/lox mice that express normal levels of HO-1, but not
in LysMCreHmox1D/D in which HO-1 expression is inhibited in myeloid cells, including the microglia. Innovation:
This study suggests the participation of the microglial a7 nAChR in the brain cholinergic anti-inflammatory
pathway. Conclusion:Activation of the a7 nAChR/Nrf2/HO-1 axis in microglia regulates neuroinflammation and
oxidative stress, affording neuroprotection under brain ischemic conditions. Antioxid. Redox Signal. 19, 1135–1148.
Introduction
Ischemic damage results from a cascade of cellular andmolecular events triggered by a sudden lack of blood flow
and subsequent reperfusion of the ischemic territory. Post-
ischemic inflammation is characterized by an orderly se-
quence of events involving a rapid activation of microglial
cells, followed by infiltration of various circulating leuko-
cytes, including granulocytes (neutrophils), T-cells, and
monocytes/macrophages that irrupt in the ischemic paren-
chyma because of the blood–brain barrier (BBB) breakdown
Innovation
We demonstrate the role of microglial alpha-7 nicotinic
acetylcholine receptor (a7 nAChR) in providing neuro-
protective and anti-inflammatory actions under brain is-
chemia conditions by a mechanism that implicates the
induction of heme oxygenase-1 expression via nuclear
factor erythroid-2-related factor 2 activation. Our data
support the notion that microglial a7 nAChR might be
targeted therapeutically to modulate the brain cholinergic
anti-inflammatory pathway.
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(23, 30). The specific role of microglia in this pathological
scenario remains controversial. Microglial activation has been
linked to the upregulation of the proinflammatory cytokines
such interleukin (IL)-1b and tumor necrosis factor (TNF),
chemokines, and reactive oxygen species (ROS), which con-
tribute to tissue damage progression (18, 37). There is also an
increasing body of evidence demonstrating the protective role
of microglia in stroke. Postischemic production of TGF-b and
IL-10 by microglia may facilitate tissue repair by exerting di-
rect cytoprotective effects on surviving cells in the ischemic
penumbra and promoting the resolution of inflammation (9,
34). This notion is strongly supported by a recent study
showing the beneficial effects of human microglia trans-
planted into rats subjected to the experimental focal brain
ischemia (40).
Nicotinic acetylcholine receptors (nAChRs) are a family of
ligand-gated ion channels and are members of the Cys-loop
receptor superfamily (35). Activation of the a7 nAChR is pro-
tective against a wide variety of cytotoxic stimuli, such as
glutamate (53), oxygen and glucose deprivation (OGD) (15),
and kainic acid (50). In recent years, nAChRs were shown to
regulate inflammation, in particular via the a7 nAChR activa-
tion in macrophages (61), which regulates the cholinergic anti-
inflammatory pathway (26, 28, 48, 61). The transcripts for the
nAChR subunits a7, a3, a5, as well as b4 have been detected in
multiple inflammatory cell types, including macrophages and
microglia, the resident macrophages of the brain (16, 47).
The transcription factor Nrf2 (nuclear factor erythroid-2-
related factor 2) is a master regulator of redox homeostasis
(22). Nrf2 controls the expression of phase II enzymes that act
in a cytoprotective manner against oxidative stress, including
heme oxygenase-1 (HO-1) (2) and the catalytic subunit of
glutamate cysteine ligase (GCL-c). HO-1 serves a vital meta-
bolic function as the rate-limiting step in the oxidative ca-
tabolism of heme to generate carbon monoxide (CO),
biliverdin, and ferrous iron (56); biliverdin is subsequently
converted to bilirubin by biliverdin reductase. These three
byproducts, and in particular CO, have been related to cyto-
protection (5) during ischemic injury, (1) including cerebral
ischemia (27, 60, 65). Moreover, CO regulates monocyte/
macrophage activation (42), an effect associated with protec-
tion against different experimental models of disease (43, 51).
Induction of HO-1 expression by different nicotinic receptor
agonists and its importance in the maintenance of anti-
inflammatory effects have been recently reported (57). On the
other hand, induction ofGCL-c, the rate-limiting enzyme of the
novo synthesis of glutathione (GSH), by melatonin increases
the levels of GSH and protects against oxidative stress (58).
Although the participation of a7 nAChR in the cholinergic
anti-inflammatory pathway is well documented in the pe-
riphery (61), there is little evidence related to its participation in
the central nervous system. In this context, we used a highly
selective microglial-target toxin and the selective a7 nAChR
agonist PNU282987 to evaluate the neuroprotective and anti-
neuroinflammatory effects of themicroglial a7 nAChRs. Further,
we used Nrf2-deficient (Nrf2- /- ) mice and LysMCreHmox1D/D
mice to assess the participation of this transcription factor in the
regulation of HO-1 in the microglial cells and in the neuropro-
tective effect mediated by a7 nAChR activation. We found that
microglial-a7 nAChR activation is crucial in the neuroprotective
effect afforded by PNU282987, an effect mediated via a mech-
anism involving Nrf2 activation and HO-1 expression.
Results
Cell death induced by OGD in OHCs
We first established the experimental conditions required
to test the protective role of the a7 nAChR agonist
PNU282987. To determine the optimum period of OGD and
reoxygenation (Reox), organotypic hippocampal cultures
(OHCs) were subjected to 15 or 30min of OGD followed by a
24- or 48-h Reox period. Cell death was measured in the CA1
subfield, which is considered to be the most vulnerable to
hypoxia/anoxia (63). OGD for 15 or 30min increased cell
death by 177%–161% and 234%–243%, as compared to nor-
moxia, respectively. No significant differences were found
between 24- and 48-h Reox, independently of the OGD peri-
ods applied (Fig. 1). We therefore selected 15-min OGD fol-
lowed by 24-h Reox as the standard protocol to perform the
following studies.
Effect of post-OGD administration of the a7 nAChR
agonist PNU282987 on OHC viability
To evaluate the protective properties of a7 nAChR, OHCs
were treated with the a7 nAChR agonist PNU282987 at dif-
ferent concentrations (1, 3, and 10 lM) during the 24-h Reox
period (see protocol in Fig. 2A). OGD (15min) followed by
Reox (24 h) increased cell death as assessed by propidium
iodide (PI) fluorescence in CA1 (compare the basal condition
in Fig. 2B with Fig. 2C). Post-OGD treatment with increasing
concentrations of PNU282987 reduced PI staining (Fig. 2D–F).
PNU282987 significantly reduced cell death measured as PI
uptake at the concentrations of 10 lM (110% – 10%) and 30lM
(142% – 12%) in comparison to OHCs subjected to OGD alone
(180% – 2%) (Fig. 2G).
FIG. 1. Oxygen and glucose deprivation (OGD) increases
cell death in organotypic hippocampal slices. Cell death
was labeled with propidium iodide (PI) fluorescence cor-
rected for the number of nuclei (Hoechst) in the CA1 subfield
of rat organotypic slices after 15 or 30min of OGD followed
by 24 or 48 h of reoxygenation (Reox). Data are mean– SEM
of seven independent experiments, ***p< 0.001, **p < 0.01
with respect to the basal.
1136 PARADA ET AL.
The cell viability was also assessed by the colorimetric de-
termination of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT) reduction. Considering the cell
viability in basal OHCs as 100%, OGD reduced the cell via-
bility by 40%; under these experimental conditions, maximum
protection offered by PNU282987 was also achieved at 10lM
(60%; Fig. 2H). We therefore selected the concentration of
10 lM to evaluate the protective mechanism of action of a7
nAChR stimulation against OGD-induced toxicity in OHCs.
Participation of the a7 nAChR/Nrf-2/HO-1 axis
in the neuroprotective effect of PNU282987
Although it is accepted that PNU282987 is a selective a7
nAChR agonist (19), we wanted to prove that the neuropro-
tective effect of PNU 282987 is mediated by this receptor. We
used the protocol illustrated in Figure 2A in the absence or
presence of a-bungarotoxin (BGT; 100 nM), a selective a7
nAChR antagonist. Inhibition of cell death associated with
OGD/Reox by PNU282987 was abrogated by BGT (Fig. 3A),
suggesting that this protective effect is indeedmediated via a7
nAChR activation.
In other models of oxidative stress injury, the neuropro-
tective effect of PNU282987 has been suggested to be medi-
ated via a mechanism involving HO-1 (44). We tested the
involvement of this heme-catabolizing enzyme under our
experimental conditions. The protective effect of PNU282987
(10lM) was associated with a 2.2-fold increase in HO-1 ex-
pression, as detected by Western blotting and as compared
with untreated controls (Fig. 3B). This effect was reversed by
BGT, suggesting that a7 nAChR activation induces the ex-
pression of HO-1. Inhibition of cell death by PNU282987 was
also abrogated by tin (Sn)–protoporphyrin-IX (SnPP; 3lM),
an inhibitor of HO activity (Fig. 3A), corroborating the
FIG. 2. Post-OGD treatment
with the a7-nicotinic acetyl-
choline receptor (nAChR)
agonist PNU282987 protects
organotypic hippocampal cul-
tures (OHCs). (A) Protocol
used to elicit toxicity: OHCs
were exposed for 15min to
OGD followed by 24h in
the control solution (Reox).
PNU282987, when used, was
present during the 24-h Reox
period. (B–F) Microphoto-
graphs (original magnification
10· ) of the CA1 subfield
loaded with PI are shown.
(B) Untreated slice; (C) slice
exposed to OGD for 15min
followed by 24h with a fresh
medium, and slices were trea-
ted for 24h with PNU282987
after the OGD period at 3lM
(D), 10lM (E), or 30lM (F). (G)
The concentration–response
curve of PNU282987 incubated
for 24h after the OGD period,
measured as the relationship of
PI/Hoechst fluorescence in the
CA1 subfield. (H) Cell viability
was measured by the 3-(4,
5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide
(MTT) reduction activity of
the organotypic slices under
the same experimental condi-
tions as in (G). Values are ex-
pressed as mean – SEM of at
least five independent experi-
ments; ***p < 0.001, **p < 0.01
compared to the basal.
###p< 0.001, #p < 0.05 with re-
spect to OGD-treated slices in
the absence of PNU282987. To
see this illustration in color,
the reader is referred to the
web version of this article at
www.liebertpub.com/ars
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participation of HO-1 in the protective effect of PNU282987.
We evaluated the induction of GCL-c, another phase II en-
zyme. As shown in Figure 3C, PNU282987 (10 lM) increased
GCL-c expression by 1.6-fold, as comparedwith controls. This
effect was inhibited by BGT and by SnPP, suggesting that a7
nAChR activation induces the expression of phase II enzymes,
presumably conferring neuroprotection against OGD.
Given that HO-1 expression is tightly regulated by Nrf2 (2),
we setup to determine the participation of this transcription
factor in the protective effect of PNU282987. The neuropro-
tective effect of PNU282987 against OGD was lost in OHCs
from Nrf2 - /- versus Nrf2 + / + mice (Fig. 4A). This was associ-
ated with the concomitant loss of HO-1 induction in OHC
from Nrf2- /- versus Nrf2 + / + mice, treated in both cases with
FIG. 3. Protection elicited
by post-OGD treatment with
PNU282987 is mediated by
a7 nAChR and heme oxyge-
nase-1 (HO-1). (A) OHCs
were exposed to 15min of
OGD and then incubated with
10lM PNU282987 for 24h
in the presence or absence of
100nM a-bungarotoxin (BGT)
and 3lM tin (Sn)–protopor-
phyrin-IX (SnPP). Represen-
tative immunoblot of HO-1 (B)
and glutamate cysteine ligase
catalytic subunit (GCLc) (C)
induction by PNU282987 in
the absence or presence of
100nM BGT and 3lM SnPP.
The histogram represents the
densitometric quantification of
HO-1 and GCLc induction
using b-actin for normaliza-
tion. Values are mean– SEM
of six experiments, ***p< 0.001
compared with the untreated-
slices, ###p<0.001, #p<0.05with
respect to the OGD-treated
slices, $$$p< 0.001, $$p< 0.01,
and $p < 0.05 compared with
the PNU282987 slices.
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PNU282987 (Fig. 4B). This suggests that the protective effect
of PNU282987 acts via a mechanism that involves the in-
duction of HO-1 by Nrf2.
Antioxidant and anti-inflammatory effect
of PNU282987
There is accumulating evidence implicating ROS and in-
flammation as pivotal mediators of acute responses of the
brain to ischemia and its chronic pathogenic progression (25,
31). OGD (15min) followed by Reox (24 h) doubled the
amount of ROS (measured byH2DCFDA) produced in OHCs,
as compared to the control (Fig. 5A). PNU282987 (10 lM) re-
duced ROS production significantly, as compared to the un-
treated controls. This effect was blocked by SnPP and by BGT
as well, suggesting that the antioxidant effect triggered upon
a7 nAChR activation is mediated by a mechanism involving
HO-1.
To test the effects of PNU282987 on the production of cy-
tokines induced by OGD/Reox, TNF and IL-10 were quanti-
fied by an enzyme-linked immunosorbent assay (ELISA) in
the culturemedium ofOHCs. OGD (15min) followed by Reox
(24 h) increased TNF secretion, as compared to the control
OHCs (477 – 50 pg/ml vs. 109 – 22 pg/ml). Treatment of
OHCswith PNU 282987 10 lM reduced TNF release almost to
the control levels (163 – 22 pg/ml). This inhibitory effect was
prevented by SnPP (3 lM) as well as by BGT (100 nM)
(429– 59 pg/ml; 377– 82pg/ml, respectively). We did not
observe changes in IL10 secretion in any of the conditions
tested (data not shown). These results suggest that a7 nAChR
activation inhibits the production of proinflammatory cyto-
kines, TNF, via a mechanism involving the expression of
HO-1.
Participation of microglia in HO-1 induction
and neuroprotection induced by PNU282987 against OGD
PNU282987 induced by 1.5-fold the expression of HO-1 in
isolated microglial cells, as assessed by Western blot (Sup-
plementary Fig. S1; Supplementary Data are available online
at www.liebertpub.com/ars). Microglial depletion fromOHC
using Mac1–sap (39) was confirmed by ionized calcium-
binding adaptor molecule 1(IBA-1) staining (Fig. 6A, B) and
was associated with increased cell death after OGD, in com-
parison to control OHCs. The protective effect of PNU282987
against OGD was impaired in microglia-depleted OHCs, as
FIG. 4. Protection elicited by poststress treatment with
PNU282987 is associated to the nuclear factor-erythroid-2-
related factor 2 (Nrf2)/HO-1 axis. (A) Following the protocol
shown in Figure 2A, the protective effect of post-OGD
treatment with 10 lM PNU282987 was tested in organotypic
slices of Nrf2 wild-type (Nrf2+ /+ ) and null mice (Nrf2 - / - ).
Data are mean – SEM of six different experiments;
***p < 0.001 compared with the untreated-slices, ##p < 0.01
with respect to OGD. (B) shows representative immunoblots
of HO-1 induction under the different experimental condi-
tions shown in A.
FIG. 5. PNU282987 reduces cellular reactive oxygen spe-
cies (ROS) production and tumor necrosis factor (TNF)-a
release caused by OGD/Reox. (A) Effect of PNU282987 on
ROS production elicited by OGD/Reox. OHCs were sub-
jected to 15min of OGD followed by 24 h of reoxygenation in
the presence or absence of 10 lM PNU282987, 100 nM BGT,
and 3lM SnPP. (B) TNF release in the OHC supernatant
measured under the same experimental conditions. Data are
means – SEM of five independent experiments; **p < 0.01
compared with the untreated-slices, ##p< 0.01 with respect to
the OGD-treated slices, $$p < 0.01, $p< 0.05 compared with
the PNU282987-treated slices.
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compared to the nondepleted OHCs (Fig. 6C). Induction of
HO-1 expression by PNU282987 was also reduced in micro-
glia-depleted OHCs, as compared to the control OHCs (Fig.
6D). This shows that a7 nAChR activation in microglia in-
duces the expression of HO-1 in microglia.
PNU282987 reduces the cortical infarct volume
through the induction of HO-1 expression
We used the photothrombotic model of stroke in mice to
evaluate whether the protective effects of PNU282987 act
under brain ischemic conditions in vivo (10). Following the
protocol shown in Figure 7A, ischemia induced by photo-
thrombosis caused a mean cortical infarct volume of
15.7% – 0.9%. Administration of PNU282987 (10mg/kg), 1 h
postphotothrombosis, reduced the infarct volume by 40%
(9.4% – 0.4%). Administration of Zinc (III)–deuteroporphyrin
IX-2,4 bisethylene glycol (ZnDPBG; 10mg/kg), a potent HO
inhibitor that crosses the BBB (24), did not alter the infarct
volume, but prevented the neuroprotective effect of the a7
nAChR agonist PNU282987 to 14.6% – 0.8% (Fig. 7B).
To establish conclusively the involvement of HO-1, we
compared the protective effect of PNU282987 against ische-
mia induced by photothrombosis in Hmox1lox/lox mice ex-
pressing normal levels of HO-1 versus LysMCreHmox1D/D in
which HO-1 expression is inhibited specifically in myeloid
cells (see the Methods section and Supplementary Fig. S2),
including in the microglia. PNU282987 reduced the infarct
volume by 38% in Hmox1lox/lox mice, as compared to untreated
Hmox1lox/lox mice. Reduction in the infarct volume correlated
with improved motor coordination measured by hindpaw
slips in the beam-walking test (BWT) (Fig. 7E). In contrast,
PNU282987 failed to reduce the infarct volume or to improve
motor coordination in LysMCreHmox1D/D mice (Fig. 7C–E).
This reveals that the expression of HO-1 in the myeloid
compartment, and presumably in the microglia, is essential to
support the neuroprotective effect of a7 nAChR against brain
ischemia induced by photothrombosis.
Discussion
In the present study, we provide experimental evidence
in vitro as well as in vivo, pointing to the crucial role of mi-
croglia in the neuroprotective effect afforded by the selective
a7 nAChR agonist PNU282987 against brain ischemia. Al-
though there is convincing evidence that a7 nAChR activation
in macrophages exerts anti-inflammatory effects mediating
the so-called cholinergic anti-inflammatory pathway (61), few
FIG. 6. Key role of microglia in the protective effect of PNU282987. The top part of the figure illustrates immunohisto-
chemical expression of the microglial marker ionized calcium-binding adaptor molecule 1 in the CA1 pyramidal cell layer of
OHCs. (A) shows an untreated slice and (B) slices treated with 5 nM of Mac1-sap, used to deplete microglia. To elicit toxicity,
the protocol shown in Figure 2 was followed. (C) Densitometric measurements of PI uptake in depleted and nondepleted
microglia OHCs. (D) The top part of the figure shows a representative immunoblot of HO-1 induction under the same
experimental conditions as shown in (C); the bottom graph represents the densitometric quantification of HO-1, using b-actin
for normalization. Data are means – SEM of six independent experiments, ***p< 0.001, **p< 0.01 compared with the untreated
slices, ###p< 0.001, ##p< 0.01 with respect to the OGD-treated slices, $$$p < 0.001, $p< 0.05, depleted versus nondepleted slices.
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FIG. 7. PNU282987 reduces the infarct volume and promotes functional recovery in mice subjected to photothrombotic
stroke depending on HO-1 expression. (A) illustrates the protocol used, in which PNU282987 (intraperitoneal [i.p] at 10mg/
kg) and/or zinc (III)–deuteroporphyrin IX-2,4 bisethylene glycol (ZnDPBG) (i.p. at 10mg/kg) were administered 60 or 15min
after the thrombotic stroke, respectively. (B) Data are expressed as a percentage (%) of the cortical infarct volume in mice.
Note that reduction of infarct in mice receiving PNU282987 was prevented by ZnDPBG. (C)Data are expressed as the percentage
(%) of the cortical infarct volume in LysMCreHmox1D/D versus Hmox1lox/lox mice subjected to photothrombotic stroke and receiving
or not PNU282987 (10mg/kg). (D) Representative photographs of the cortical infarcts of mice represented in (C). (E)Motor skills
analyzed with the Beam-walk test 24h after ischemia by quantification of hindpaw slips (see the Materials and Methods section)
in the same animals as in (C). Data are expressed as mean– SEM of eight animals per group, in two independent experiments
with the same trend. **p<0.01, compared with the ischemia plus saline group, #p<0.05 in comparison with PNU treated animals,
***p<0.001 in comparison with Hmox1lox/lox saline mice, $$$p<0.001, $$p<0.01 LysMCreHmox1D/D versus Hmox1lox/lox. To see this
illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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studies have addressed specifically whether this effect is also
exerted in microglia, the resident macrophages of the brain.
We provide evidence that a7 nAChR activation induces the
expression of HO-1 in microglia, which is required to support
the neuroprotective effect of PNU282987 against brain ische-
mia. This notion is supported by the following independent
observations: (i) PNU282987 induces HO-1 expression at the
concentration that afforded maximum protection against
brain ischemia; (ii) the protective effect of PNU282987 is lost
by inhibition of the HO activity (Figs. 2 and 3); (iii) induction
of HO-1 by PNU282987 is ablated by deletion of the tran-
scription factor Nrf2 (Fig. 4); (iv) the protective effect of
PNU282987 is reversed by microglia deletion, an effect asso-
ciated with the loss of HO-1 expression (Fig. 6); and (v) the
protective effect of PNU282987 is ablated by specific deletion
of HO-1 in myeloid cells, including the microglia (Fig. 7).
Signaling through nAChRs plays an important role in
various processes such as neurite outgrowth, control and
synthesis of neurotrophic factors, neuroprotection (20), as
well as in the regulation of inflammation (48, 61). Moreover,
signaling via a7 nAChR protects against neuronal death in
differentmodels of hemorrhagic brain injury (13, 29).We have
also previously shown that a7 nAChR activation is protective
in different in vitro models of ischemia/Reox (15, 44). Most of
these studies have focused their attention on neuronal nico-
tinic receptors, while the participation of nAChRs in other
brain cells such as astrocytes and microglia has been less
studied. The results obtained in the present work indicate that
a7 nAChRs expressed in microglia are key elements in pro-
moting the protective effect of PNU282987. This notion is
supported by the observation that the selective a7 nAChR
antagonist a-BGT prevented the neuroprotective effect and
the induction of phase II enzymes (HO-1 and GCL-c) by
PNU282987, and hence the reduction of ROS production and
TNF release (Fig. 5). Moreover, the protective effect of
PNU282987 against brain ischemia is reduced by 70% upon
microglial deletion (Fig. 6). These observations strongly sug-
gest that the cholinergic anti-inflammatory pathway de-
scribed for peripheral macrophages, as controlling systemic
inflammation, may have a brain counterpart, where micro-
glias, the resident macrophages of the brain, regulate in-
flammation via activation of the a7 nAChRs.
Recent findings have elucidated the cellular signaling
pathways and molecular mechanisms that mediate adaptive
stress response that typically involves the synthesis of various
stress resistance proteins as the products of vitagenes, a group
of genes strictly involved in preserving cellular homeostasis
during stressful conditions (6). The vitagene family is com-
posed of the heat shock proteins (Hsp) HO-1/Hsp32, Hsp70,
and Hsp60, by the thioredoxin system and by sirtuin proteins.
Nrf-2 is a master regulator of cellular redox homeostasis,
controlling the expression of different genes that modulate the
cellular redox status and inflammation (phase II enzymes),
including HO-1 (22). Induction of HO-1 expression has gen-
erally been considered to provide an adaptive cytoprotective
response against the toxicity of oxidative stress (17, 45, 59).
Hmox1-deficient mice develop chronic inflammatory lesions
that are similar to the ones observed in individuals lacking the
HO-1 expression (64). Hence, compounds targeting the vita-
gene network could be a novel approach to delay various
alterations in cells, tissues, and organs and potentially prevent
and treat many different diseases, such as ischemia. The
mechanisms regulating the salutary effects of HO-1 remain
however to be fully established (52).
The protective effect of PNU282987 acts via activation of
Nrf2, as demonstrated by the loss of this protective effect in
OHCs from Nrf2- /- mice (Fig. 4A). This effect is associated
with inhibition of HO-1 expression in microglial cells from
OHCs Nrf2 - / - versus Nrf2 + / + (Fig. 4B and Supplementary
Fig. S2). Recently, it has been hypothesized that pharmaco-
logical modulation of Nrf2 restores the cellular redox state
through the expression of antioxidant phase II enzymes,
downmodulating the pathological neuroinflammatory re-
sponse of reactive microglia (21). Heme degradation by HO-1
in microglia generates CO (33), a gasotransmitter that can
inhibit NADPH oxidase (55), themain enzyme responsible for
microglial ROS production (4) promoting microglial activa-
tion during neuroinflammation (7). PNU282987 reduces ROS
production as well as TNF release induced by brain ischemia,
an effect mediated by the induction of HO-1 expression via a7
nAChR signaling (Fig. 5A, B). This corroborates the impor-
tance of the Nrf-2/HO-1 system in the control of the cellular
redox state and modulation of the neuroinflammatory re-
sponses to ischemia. We infer that nAChR signaling modu-
lates microglial activation via a mechanism mediated by
Nrf2/HO-1, which inhibits ROS production.
Microglias have historically been viewed as immunocom-
petent cells that respond to inflammation by acting as antigen-
presenting cells or secreting cytokines. The specific role of
microglia in postischemic inflammation remains controver-
sial. Resident microglia are activated rapidly in response to
brain injury, within minutes of ischemia onset, and produce
proinflammatory mediators, such TNF and IL-1b, which ex-
acerbate brain damage (18, 37). Our data show that cell death
induced by OGD was significantly higher in microglia-
depleted OHCs compared to nondepleted slices (Fig. 6).
Hence, in our model, microglial cells have a protective role in
the brain against ischemic injury.
We found that expression of HO-1, presumably in the mi-
croglia, mediates the protective effect of PNU282987 against
photothrombotic brain ischemia, as assessed in Hmox1lox/lox
mice, expressing the normal levels of HO-1 versus LysMCre
Hmox1D/D, in which HO-1 expression is inhibited specifically
in myeloid cells, including in the microglia. Together with
the data obtained in the OHC model, this suggests that ex-
pression of HO-1 by microglia is important to resolve the
oxidative stress and neuroinflammation and, most impor-
tantly, to stop the progression of cell death induced by an
ischemic episode. This is in line with the notion that micro-
glia plays a central role in the regulation of brain ischemia
and excitotoxic injury (32, 40, 41). We propose that phar-
macologic modulation of HO-1 in microglia may be consid-
ered as a potential strategy against a brain ischemia-induced
injury (62).
Materials and Methods
Animals and preparation of OHC
OHCs were conducted on 8–10-day-old Sprague-Dawley
rats or wild-type C57BL/6 mice and Nrf2-knockout mice of
the same littermates. Nrf2-knockout mice were kindly pro-
vided by Dr. Antonio Cuadrado (Department of Biochem-
istry, School ofMedicine, UniversidadAuto´noma deMadrid).
All animal assays were carried out following the European
1142 PARADA ET AL.
Community Council Directive issued for these purposes and
were approved by the Ethics Committee of the Facultad de
Medicina, Universidad Auto´noma de Madrid. Every effort
was made to minimize the number of animals used and their
suffering.
Cultures were prepared according to the methods de-
scribed by Stoppini et al. (54) with somemodifications. Briefly,
300-lm-thick hippocampal slices were prepared from rat or
mice pups using a McIlwain tissue chopper, and separated in
ice-cold Hank’s balanced salt solution (HBSS) composed of
(mM): glucose 15, CaCl2 1.3, KCl 5.36, NaCl 137.93, KH2PO4
0.44, Na2HPO4 0.34, MgCl2 0.49, MgSO4 0.44, NaHCO3 4.1,
and HEPES 25; 100U/ml penicillin and 0.100mg/ml genta-
micin. Approximately 4–6 slices were placed on Millicell 0.4-
lm culture insert (Millipore) within each well of a six-well
culture tray with the medium, where they remained for 7
days. The culture medium, which consisted of 50% minimal
essential medium, 25%HBSS, and 25% heat-inactivated horse
serum, were purchased from Life Technologies. The medium
was supplemented with 3.7mg/ml d-glucose, 2mmol/l l-
glutamine, and 2% of B-27 Supplement Minus antioxidants
(Life Technologies), and 100U/ml penicillin. OHCs were
cultivated in a humidified atmosphere at 37C and 5% CO2,
and the medium was changed twice a week.
Mice
C57BL/6 Nrf2 -/- (22) and Hmox1LoxP (38) mice were
generated by the laboratory of Dr. Masayuki Yamamoto
(Tohoku University Graduate School of Medicine) and ob-
tained through the RIKEN BioResource Center (Nrf2 -/-
mouse/C57BL6J and B6J.129P2-Hmox1 < tm1Mym > ).
C57BL/6 LysMCre mice were generated by the laboratory of
Dr. Forster (8) and obtained through the Jackson Laboratory
(B6.129P2-Lyz2tm1(cre)Ifo/J Stock Number:004781). LysM-
CreHmox1D/D mice used in this study were generated at the
Instituto Gulbenkian de Cieˆncia from LysMCreHmox1D/D ·
LysM
Cre
Hmox1D/D. The LysMCreHmox1D/D offspring is homo-
zygous for the LysMCre allele. Mice were genotyped by the
polymerase chain reaction (PCR) from genomic DNA using
the following primers for the Hmox1 allele (Hmox1 wild-type
forward 5¢-CTCACTATGCAACTCTGTTGGAGG-3¢, Hmox1
wild-type reverse 5¢-GTCTGTAATCCTAGCACTCGAA-3¢
and Hmox1LoxP reverse 5¢-GGAAGGACAGCTTCTTGTA
GTCG-3¢) and for the LysMCre allele (mutant 5¢-CCCAGA
AATGCCAGATTACG-3¢; common: 5¢-CTTGGGCTGCCAG
AATTTCTC-3¢ and wild type 5¢-TTACAGTCGGCCAG
GCTGAC-3¢). Mice were bred at the Instituto Gulbenkian de
Cieˆncia with food and water provided ad libitum. Mice were
used at 6 to 12 weeks of age, and the littermates were used as
controls.
Thioglycollate-induced peritoneal macrophages
Briefly, mice received (intraperitoneal [i.p], 2ml) a 3%
thioglycollate solution (w/v), and macrophages were ob-
tained by peritoneal lavage 5 days, thereafter in phosphate-
buffered saline (PBS; 5ml).
Peritoneal macrophages were stained with an Alexa467-
conjugated-anti-CD11b (M1/70; 1:50 dilution) mAb, and
nonspecific Fc binding was inhibited using an anti-FcgIII/II
receptor antibody (2.4G2; 1:50 dilution) in PBS 2% fetal calf
serum (FCS) (20min, 4C). After washing and centrifugation
(PBS 2% FCS; 666g, 2min, 4C), cells were sorted as CD11b+
for the Hmox1lox/lox and as CD11b+DsRed+ or CD11b+DsRed-
for the LysMCreHmox1D/D. Cells were collected and analyzed by
flow cytometry (FACSAria; BD Biosciences), using BD FACS-
Diva Software (BD Biosciences) for acquisition. Postacquisition
analysis was performed with FloJo software (Treestar).
RNA isolation and qRT-PCR
Briefly, mRNAwas isolated from CD11b + -sorted cells and
extracted with the RNeasy Mini Kit (Qiagen). cDNA was
synthesized from 0.3–0.5 lg of RNA using random hexamer
primers (0.3mg/reaction; Invitrogen) and dNTPs (0.5mM/
reaction; Invitrogen) (5min, 65C). 5· First Strand buffer
(Invitrogen) was added in the presence of dithiothreitol
(10mM/reaction; Invitrogen) and RNAse Out recombinant
ribonuclease inhibitor (40U/reaction; Invitrogen) (2min,
42C). SuperScriptII reverse transcriptase (200U/reaction;
Invitrogen) was added completing a final volume of 20 ll
(50min, 42C; 15min, 70C). One ll of cDNA was used for
PCRs (10ll) using the Power SYBRGreen PCR master mix
(Applied Biosystems) and optimal primer concentrations
(previously determined for each transcript). PCR products
were detected by quantitative real time-PCR (ABI-7900HT;
Applied Biosystems) (2min, 50C, 10min, 95C, and 40 cycles
of 15 s at 95C, 1min, 60C). Primers used to amplify mouse
mRNA transcripts were designed using the Primer3 software
(Whitehead Institute for Biomedical Research, Steve Rozen
and Helen Skaletsky) according to the specifications of the
ABI-7900HT equipment (Applied Biosystems) and are listed
below: Hmox1 5¢-AAGGAGGTACACATCCAAGCCGAG-3¢
and 5¢-GATATGGTACAAGGAAGCCATCACCAG-3¢; Gly-
ceraldehyde 3-phosphate dehydrogenase (GAPDH) 5¢-AAC
TTTGGCATTGTGGAAGG-3¢ and 5¢-ACACATTGGGGG
TAGGAACA-3¢. The transcript number was calculated from
the Ct of each gene using a 2 -DDCT method (relative number)
and normalizing results to GAPDH.
Oxygen–glucose deprivation in OHCs
Oxygen–glucose deprivation was used as an in vitro model
of cerebral ischemia. The inserts with slice cultures were
placed in 1ml of OGD solution composed of the following (in
mM): NaCl 137.93, KCl 5.36, CaCl2 2, MgSO4 1.19, NaHCO3
26, KH2PO4 1.18, and 2-deoxyglucose 11 (Sigma-Aldrich). The
cultures were then placed in an airtight chamber (Billups and
Rothenberg), and were exposed to 5min of 95% N2/5% CO2
gas flow to ensure oxygen deprivation. After that, the cham-
ber was sealed for 15min at 37C. The control cultures were
maintained for the same time under a normoxic atmosphere
in a solution with the same composition as that described
above (OGD solution), but containing glucose (15mM) in-
stead of 2-deoxyglucose. After the OGD period, the slice
cultures were returned to their original culture conditions for
24 h (reoxygenation period).
Quantification of cell death in OHCs
Quantification of viability by MTT. The cell viability, vir-
tually the mitochondrial activity of living cells, was measured
using the quantitative colorimetric assay of MTT, as described
previously (11) with some modifications. Briefly, 1ml of the
MTT-labeling reagent, at a final concentration of 0.5mg/ml,
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was added to the medium of each well at the end of the OGD-
Reox period or normoxic period, and the plate was placed in a
humidified incubator at 37C with 5% CO2 and 95% air (v/v)
for an additional 30min. Then, the insoluble formazan was
dissolved with dimethyl sulfoxide; the colorimetric determi-
nation of MTT reduction was measured at 540 nm. Control
cells treated under normoxic conditions with vehicle were
taken as 100% viability.
Propidium iodide uptake. Cell death was determined in
the CA1 region by staining the OHCs with PI. Thirty minutes
before analyzing fluorescence, slices were incubated with PI
(1 lg/ml) and Hoechst (5lg/ml); Hoechst staining was used
to normalize PI fluorescence with respect to the number of
nuclei. Fluorescence was measured in a fluorescence-inverted
NIKON Eclipse T2000-U microscope. The wavelengths of
excitation and emission for PI and Hoechst were 530 or 350,
and 580 or 460 nm, respectively. Images were taken at CA1 at
magnifications of 10· . The Metamorph programme version
7.0. was used for fluorescence analysis. To calculate cell death,
we divided the mean PI fluorescence by the mean Hoechst
fluorescence, as previously described (14). Data were nor-
malized with respect to the control values that were consid-
ered as 1.
ROS measurement in OHCs
To measure the cellular ROS, we used the molecular probe
H2DCFDA as previously described (44). Briefly, organotypic
hippocampal slices were loaded with 10lM H2DCFDA,
which diffuses through the cell membrane and is hydrolyzed
by intracellular esterases to the nonfluorescent form di-
chlorofluorescein (DCFH). DCFH reacts with intracellular
H2O2 to form dichlorofluorescin, a green fluorescent dye.
Fluorescence was measured in a fluorescence-inverted NI-
KON Eclipse T2000-U microscope. Wavelengths of excitation
and emission were 485 and 520 nm, respectively.
Determination of cytokine levels in the culture
medium of OHCs
TNF and IL-10 levels were measured by using specific
ELISA kits. Supernatant samples were obtained at the indi-
cated times and subjected to the ELISA analysis according
to the recommendations of the supplier (R&D Systems-
BioNova).
Immunotoxic depletion of microglial cells in OHCs
Hippocampal slices were cultured for 5 days and then ex-
posed to 3 or 5 nM of the immunocomplex Mac1–sap (Ad-
vanced Targeting Systems) for 7 days. At the end of this
period, the slices were fixed with paraformaldehyde 4% for
immunohistochemistry. The OGD experiments in microglia-
depleted OHCs were performed at the end of the im-
munotoxic treatments.
Histochemistry for microglia
The OHCs were fixed with 4% paraformaldehyde in 0.1 M
phosphate buffer (PB, pH 7.4) and were subsequently cryo-
protected for 2 days in 30% sucrose in 0.1 M PB. The endog-
enous peroxidase was inactivated with 1% H2O2, and the
OHCs were then incubated in a blocking solution (PBS, 10%
bovine serum albumin, and 10% normal goat serum) for 1 h,
and rabbit anti-IBA1 was used as the primary antibody 1:1000
(Wako Chemicals, Rafer S.L) overnight. The secondary anti-
body was biotinylated goat anti-rabbit (Vector Labs; 1:200;
2 h) andwas dissolved in a blocking solution. The OHCswere
incubated in an avidin–biotin peroxidase complex (Kit ABC
Elite, 1:250 in PBS; Vector Laboratories) for 2 h and reacted
with diaminobenzidine (0.05%; Sigma) with H2O2 (0.003% of
the stock 30% solution). The intensity of the staining was
checked every few minutes under a microscope, and when
labeling was satisfactory, the reaction was stopped by rinsing
the OHCs with a cold PB. After several washes with PB, the
OHCs were dehydrated in ethanol, defatted with xylene, and
coverslippedwith DePeX. Negative controls for the specificity
of the secondary antibody were prepared by omitting the
primary antibody.
Immunoblotting and image analysis
After treatments, the slices were carefully separated from
the inserts and lysed in 100 ll ice-cold lysis buffer (1%Nonidet
P-40, 10% glycerol, 137mM NaCl, 20mM Tris–HCl, pH 7.5,
1 lg/ml leupeptin, 1mM phenylmethylsulfonyl fluoride,
20mM NaF, 1mM sodium pyrophosphate, and 1mM
Na3VO4). Protein (30lg) from this cell lysate was resolved by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis
and transferred to the Immobilon-P membranes (Millipore
Corp.). The membranes were incubated with anti-HO-1 (1:1000;
Chemicon), anti-GCLc subunit (1:10000; a generous gift fromDr
Cuadrado A), or anti-b-actin (1:100,000; Sigma). Appropriate
peroxidase-conjugated secondary antibodies (1:10,000) were
used to detect the proteins by enhanced chemiluminescence.
Different band intensities corresponding to immunoblot detec-
tion of protein samples were quantified using the Scion Image
program. Immunoblots correspond to a representative experi-
ment that was repeated 4–5 times with similar results.
Microglial cell culture
Microglias were isolated using a mild trypsinization
method as previously described (49) with brief modifications.
Mixed glial cultures were prepared from the cerebral cortices
of 3-day-old Sprague-Dawley rats. After mechanical dissoci-
ation, cells were seeded in Dulbecco’s modified Eagle’s
medium (DMEM)/F12 with 20% of fetal bovine serum (FBS)
at a density of 300,000 cells/ml and cultured at 37C in hu-
midified 5% CO2/95% air. The medium was replaced after 5
days in vitro (DIV) for DMEM/F12 with 10% FBS. The con-
fluency was achieved after 10–12 DIV. High enriched micro-
glial cultures were obtained with a trypsin solution (0.25%
trypsin and 1mM EDTA) diluted 1:4 in DMEM-F12. This
process resulted in the detachment of an upper layer of cells in
one piece, and microglial cells were attached to the bottom of
the well. A great majority of cells (99%) were positive for
CD11b, as judged by the immunocytochemical criteria.
Photothombotic stroke model
All animal assays were carried out following the European
Community Council Directive issued for these purposes and
were approved by the Ethics Committee of the Facultad de
Medicina, Universidad Auto´noma de Madrid. Every effort
was made to minimize the number of animals used and their
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suffering. Mice were housed individually under controlled
temperature and lighting conditions with food and water
provided ad libitum. To induce ischemia, animals were an-
esthetized with 1.5% isoflurane in oxygen under spontaneous
respiration. Mice were then placed in a stereotaxic frame
(David Kopf Instruments), and the body temperature was
maintained at 37C– 0.5C using a servo-controlled rectal
probe-heating pad (Cibertec). A midline scalp incision was
made, and the skull was exposed with removal of the peri-
osteum, and both the bregma and lambda points were iden-
tified. A cold light (Zeiss KL 1500 LCD) was centered using a
micromanipulator at 0.2mm posterior and 1.5mm lateral to
bregma on the right side using a fiber optic bundle of 2mm in
diameter. According to the Paxinos mouse brain atlas, the
primary motor cortex, secondary motor cortex, and primary
somatosensory cortex (hindlimb and forelimb) are lying be-
neath this stereotaxic position. One milligram (0.1ml) of the
photosensitive dye Rose Bengal (Sigma-Aldrich) dissolved in
sterile saline was injected i.p., and 5min later, the brains were
illuminated through the intact skull for 20min. After com-
pletion of the surgical procedures, the incision was sutured,
and the mice were allowed to recover.
Drug administration protocol
Mice were randomly divided into four groups: subjected to
ischemia and treated with 0.9% NaCl sterile saline (ischemia
control group), treated with 10mg/kg PNU282987 dissolved
in saline containing 5% DMSO, treated with ZnDPBG dis-
solved in DMSO, and diluted in physiological saline at a dose
of 10mg/kg (12), or with the combination of PNU282987 and
ZnDPBG at the concentrations mentioned above. PNU282987
and ZnDPBG treatments were given i.p after ischemia (1 h
and 15min, respectively).
Measurement of infarct volume
Animals were sacrificed by decapitation 24 h after the is-
chemic insult. The brainswere quickly removed and coronally
sectioned into 1-mm-thick slices. For delineation of the infarct
area, the brain slices were incubated in a 2% solution of tri-
phenyltetrazolium chloride and then fixed in a buffered for-
malin solution, and the unstained area was defined as
infarcted tissue. Morphometric determination of the cortical
infarct volume was obtained using an unbiased stereological
estimator of volume based on Cavalieri’s principle (3).
Beam-walk test
Motor coordination of mice was assessed 24 h after the
photothrombotic stroke by measuring the number of contra-
lateral hindpaw slips in the Beam-walk apparatus (36, 46).
This test takes place over three consecutive days: 2 days of
training and 1 day of testing. In the BWT, mice have to go
through a 520-mm beam with a flat surface of 10-mm width
resting 50 cm above the tabletop on two poles. A black goal
box (150mm · 150mm · 150mm) is placed at the end of the
beam as the finish point. The amounts of hindpaw slips that
occur in the process were counted.
Statistics
Data are given as mean– SEM. Differences between the
groups were determined by applying a one-way ANOVA
followed by a Newman–Keuls post-hoc or two-way ANOVA,
followed by a Bonferroni post hoc test when appropriate.
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Abbreviations Used
BBB¼ blood–brain barrier
BGT¼ bungarotoxin
BV¼ biliverdin
CO¼ carbon monoxide
DCFH¼dichlorofluorescein
ELISA¼ enzyme-linked immunosorbent assay
GCL-c¼ glutamate cysteine ligase catalytic subunit
GSH¼ glutathione
HBSS¼Hank’s balanced salt solution
HO-1¼hemoxygenase-1
IBA1¼ ionized calcium-binding adaptor molecule 1
IL¼ interleukin
MTT¼ 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide
nAChR¼nicotinic acetylcholine receptor
NADPH¼nicotinamide adenine dinucleotide phosphate
NOX¼NADPH oxidase
Nrf2¼nuclear factor-erythroid-2-related factor 2
OGD¼ oxygen and glucose deprivation
OHCs¼ organotypic hippocampal cultures
PBS¼phosphate-buffered saline
PI¼propidium iodide
Reox¼ reoxygenation
ROS¼ reactive oxygen species
SnPP¼ tin (Sn)–protoporphyrin-IX
TNF¼ tumor necrosis factor
ZnDPBG¼ zinc (III)–deuteroporphyrin IX-2,4
bisethylene glycol
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